Fortive Corp

NYSE: FTV·Everett, Washington·

Price
$67.53
Base IV
$27.81

Valuation snapshot

Above bull case

At $67.53, the price is above even our bull case of $45.66.

Values per share, from an .

No growth
…
Loading earnings power
Base case
$27.81
41% of the price · range $9.43–$45.66
Price vs base case
143% above
$67.53 against $27.81
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $9.43 to bull $45.66. Values per share.

Price against each value

Bear case
$9.43
Price 616% above
No growth
…
—
Base case
$27.81
Price 143% above
Researched bygpt-6-sol
Valuation Oct 29, 2026 · Price as of Nov 16, 2026How we got here

What does Fortive do?

Fortive Corp provides instrumentation, software, and services to help industrial and healthcare professionals manage safety, maintenance, and clinical workflows.

It brought in $4.4B of sales in the 12 months to Oct 2026.

Led by Olumide Soroye, President and Chief Executive Officer since 2025. Fortive Corporation Form 8-K Current Report

Fluke 87V industrial multimeter · June 2024Image: Fluke
Industry
Semiconductors
Based in
Everett, Washington
Trades on
NYSE as FTV

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Oct 2026, about 15¢ was left as profit after every cost, interest and tax. The biggest cost is sales, marketing and admin, 38¢ of every dollar.

  • Making what it sells37¢
  • Research and development6¢
  • Sales, marketing and admin38¢
  • Interest and other costs3¢
  • Tax2¢
  • Left as profit15¢
Totals of the four quarters to Oct 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Fortive, and for what?

Fortive sells instruments, software and services used in industrial work and healthcare. It earns revenue by designing, making and marketing these products and solutions through two segments: Intelligent Operating Solutions and Advanced Healthcare Solutions.

Its customers are businesses and healthcare providers, including manufacturers, utilities, hospitals and other organizations; government entities are also customers.

  • Intelligent Operating Solutions

    69%

    Professional instruments, facilities and asset software, and connected worker safety and compliance products and services.

    Fluke 87V industrial multimeter · June 2024Image: Fluke
  • Advanced Healthcare Solutions

    31%

    Sterilization, instrument tracking, biomedical testing, radiation safety and clinical productivity products and services.

    Fluke Biomedical ESA615 electrical safety analyzerImage: Fluke Biomedical
Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Advanced Sterilization Products (ASP) headquarters and operations — Irvine, United States. ASP's Irvine headquarters runs Fortive's STERRAD low-temperature sterilization business, which has about 1,400 employees and was bought from J&J for about $2.7B; it is the core of the Advanced Healthcare Solutions segment and its recurring consumables revenue.
  • Industrial Scientific global headquarters — Pittsburgh, United States. This roughly 200,000 sq ft Pittsburgh-area campus is home to Industrial Scientific, which Fortive owns and which designs and makes gas-detection instruments and sells connected-safety subscriptions in the Intelligent Operating Solutions segment.
  • Fluke Calibration American Fork site — American Fork, United States. Fluke Calibration, a division of Fortive's Fluke unit, runs accredited calibration laboratories and a primary temperature calibration lab here, which support Fluke's precision calibration instruments and its recurring service revenue.
See them on the globe

Fortive 2025 Form 10-K

How is the business doing?

Sales shrank from $4.6B in 2020 to $4.2B in 2025, about 2% a year.

Running the business leaves about 20¢ of each sales dollar as operating profit, up from 12¢ in 2020.

After paying for its upkeep and new investment, it had $1.1B of cash to spare in the 12 months to Oct 2026.

Sales$4.2B
20162025
Operating margin17%
20162025
Free cash flow$966.4M
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Fortive says it exists to create essential technologies that help keep people safe and work productive.

“innovating essential technologies to keep our world safe and productive”

Fortive 2025 Form 10-K

Who is responsible for the plan?

Roles checked November 14, 2026.

What management says it is working on now:

  • Grow the business profitably

    Management says it is accelerating organic growth through its Fortive Business System, with investments in innovation, commercial capabilities and more recurring customer value.

    Fortive Q3 2026 earnings release
  • Allocate capital with discipline

    Management says it is returning capital through share repurchases while pursuing selected smaller acquisitions that meet its strategic and financial criteria.

    Fortive Q3 2026 earnings call transcript
  • Build investor trust

    Fortive lists building and maintaining investor trust as a pillar of its strategy.

    Fortive Q3 2026 earnings release
Adjusted diluted earnings per share, FY 2026
$3.10 to $3.14
Fortive Q3 2026 earnings release
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is picking up. In Q3 2026 it sold 8% more than a year earlier. The year before, quarters averaged 6%.

Its operating margin is wider than a year ago: 21¢ per sales dollar, against 16¢.

Since Oct 2026 the share price has risen 3%, from $65.84 to $67.53.

Bull $45.66Base $27.81Bear $9.43Oct 30Nov 16 · $67.53
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

  • Expected in early 2027; date not yet specified

    Full-year 2026 results and outlook

    Fortive’s next scheduled quarterly results release is expected to report on the fourth quarter and full year 2026, offering an update on its business and guidance.

    Fortive Q3 2026 earnings release

Our own estimate moved too: the base case went from $24.91 to $27.81 a share between our last two valuations. The biggest reason: Quarterly capital expenditures to sales moved from an unreported prior value to 2.7%, as reported in Q3 2026 results, trailing cash-flow schedule.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Economic slowdowns and shifting customer demand

    A weaker economy or lower customer spending could reduce demand, delay orders and increase price competition. Several businesses also depend on customers’ capital spending plans.

    From the company's own filingsWould hit how fast sales growFortive 2025 Form 10-K

  2. Competition and product innovation

    Fortive operates in competitive markets where products and technology change quickly. If it cannot develop products customers adopt, or compete on price and service, sales and margins could suffer.

    From the company's own filingsWould hit how fast sales growFortive 2025 Form 10-K

  3. Supply chain and input costs

    Shortages, delays or higher prices for components and materials could disrupt production and raise costs. Fortive may not be able to pass those increases on to customers.

    From the company's own filingsWould hit how much of each sale it keepsFortive 2025 Form 10-K

  4. Healthcare rules and compliance

    Some healthcare products are regulated medical devices, and Fortive must meet safety, quality, privacy and marketing rules. Failure to comply could lead to penalties, product restrictions or added costs.

    From the company's own filingsWould hit how fast sales growFortive 2025 Form 10-K

  5. Cybersecurity and AI

    Cyberattacks could disrupt operations or expose confidential information. Fortive also says AI use brings risks involving accuracy, privacy, security and intellectual property.

    From the company's own filingsWould hit how fast sales growFortive 2025 Form 10-K

  6. Trade policy and international exposure

    About 44% of 2025 sales came from outside the United States. Tariffs, sanctions, currency moves or regional conflict could raise costs or make it harder to sell and deliver products.

    From the company's own filingsWould hit how fast sales growFortive 2025 Form 10-K

  7. Full-year 2025 core growth was only 0.017, and Q3 2026 healthcare core growth was 0.031.

    From our researchWould hit how fast sales growFull-year 2025 results

  8. Advanced Healthcare Solutions' Q3 GAAP operating margin declined to 0.112 from 0.129.

    From our researchWould hit how much of each sale it keepsQ3 2026 results

Is it a good business?

From 2016 to 2025 it earned between 4% and 21% on the capital invested in it, a median of 7%. Its cost of capital in the latest valuation is 8.5%; returns were above it in 3 of the 10 years.

From 2016 to 2025 it earned between 6% and 44% on its shareholders' equity, a median of 9%.

Over 10 years its operating margin ranged from 12¢ to 20¢ per sales dollar, a median of 17¢. Gross margin ran from 49¢ to 64¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital7%
20162025

Cost of capital 8.5%

Return on equity9%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 13%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 8.8% in a year, so each remaining share owns a slightly bigger slice.

It owes $3.1B more than it holds in cash, about 3.6 years of operating profit.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $67.53. Our put its value between $9.43 and $45.66, with $27.81 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $9.43

Fortive's recent sales improvement fades, and its weaker healthcare business holds back future profits.

Base case, $27.81

Fortive keeps much of this year's faster sales growth and gradually earns more from those sales, though growth slows over time.

Bull case, $45.66

Fortive builds on this year's faster sales, its healthcare business improves, and each additional sale contributes more profit.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects far more than we do.Price above value: 143%

For Fortive to be worth today's $67.53, sales would need to grow about 23.8% a year. We assume 6.0%. Over the last 5 years, sales shrank 3.3% a year.

−10%0%+10%+20%+30%Past 5 yrs −3.3%We assume 6.0%Price needs 23.8%

Or, if sales grow 6.0% as we assume, the price works with a profit margin of 44.9% (we assume 22.0%).

Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.

Do you think sales can grow 23.8% a year?

Try your own numbers

We're moderately sure of this range: it scores 52 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $27.81 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average6.0%
  • Operating margin22.0%
  • Long-term growth rate2.5%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$27.81 -58.8%

Build